Company Oncobiologics Inc Nasdaq

Equities

US68235M2044

Biotechnology & Medical Research

Business Summary

Managers

Members of the board

Share class

Shareholders

Company contact information

Sector

Sector Other Biotechnology & Medical Research

Inactive Instrument

End-of-day quote Nasdaq Other stock markets
- ^USD	-

05-28	Outlook Therapeutics Granted EU Marketing Authorization for Lytenava to Treat Wet AMD	MT
05-28	Outlook Therapeutics, Inc. Receives European Commission Marketing Authorization for LYTENAVA? (bvacizumab grapa) for the Treatment of Wet AMD	CI

Outlook Therapeutics, Inc. is a biopharmaceutical company. The Company focuses on developing and commercializing ONS-5010 (LYTENAVA (bevacizumab-vikg)), an ophthalmic formulation of bevacizumab for use in retinal indications. The Company's product candidate, ONS-5010, is developed to be administered as an intravitreal injection for the treatment of wet age-related macular degeneration (wet AMD), diabetic macular edema (DME), and branch retinal vein occlusion (BRVO). Bevacizumab is a full-length, humanized anti-Vascular Endothelial Growth Factor (VEGF) recombinant monoclonal antibody (mAb), that inhibits VEGF and associated angiogenic activity. VEGF is a protein that promotes the growth of new abnormal blood vessels. Its biologics license application (BLA) for ONS-5010 in wet AMD involved three clinical trials, which include NORSE ONE, NORSE TWO and NORSE THREE. The Company sells ONS-5010 in the United States, United Kingdom, Europe, Japan and other markets.

Managers	Title	Age	Since
C. Trenary CEO	Chief Executive Officer	66	06/07/21
Lawrence Kenyon DFI	Director of Finance/CFO	58	14/09/15
Surendra Sharma CTO	Chief Tech/Sci/R&D Officer	-	18/01/23
Terry Dagnon COO	Chief Operating Officer	62	31/10/18
Alicia Tozier SAM	Sales & Marketing	-	01/03/22
Joel Prieve PRN	Corporate Officer/Principal	-	07/02/22
Jeff Evanson PRN	Corporate Officer/Principal	55	31/10/18
Jennifer Kissner PRN	Corporate Officer/Principal	-	25/04/19

Members of the board	Title	Age	Since
Randy Thurman CHM	Chairman	74	12/04/18
Kurt Hilzinger BRD	Director/Board Member	63	10/12/15
C. Trenary CEO	Chief Executive Officer	66	06/07/21
Lawrence Kenyon DFI	Director of Finance/CFO	58	14/09/15
Yazan Haddadin BRD	Director/Board Member	48	30/10/17
Julian Gangolli BRD	Director/Board Member	66	19/04/20
Gerd Auffarth BRD	Director/Board Member	59	19/04/20
Julia Haller BRD	Director/Board Member	69	10/08/22
Faisal Ghiath Munir Sukhtian BRD	Director/Board Member	39	10/09/17
Andong Huang BRD	Director/Board Member	27	18/06/20

	Vote	Quantity	Free-Float	Company-owned shares	Total Float
Stock A	1	23,405,637	14,743,307 ( 62.99 %)	0	62.99 %

Name	Equities	%	Valuation
Gms Ventures & Investments 14.96 %	3,502,360	14.96 %	25 M $
Syntone Technologies Group Co. Ltd. 7.286 %	1,705,438	7.286 %	12 M $
Tang Capital Management LLC 6.919 %	1,619,412	6.919 %	11 M $
Jeffrey Robert Jay 6.323 %	1,480,000	6.323 %	10 M $
Great Point Partners LLC 6.323 %	1,480,000	6.323 %	10 M $
Tenshi Healthcare Pte Ltd. 3.554 %	831,851	3.554 %	6 M $
Armistice Capital LLC 3.052 %	714,285	3.052 %	5 M $
Sphera Funds Management Ltd. 2.441 %	571,429	2.441 %	4 M $
Caligan Partners LP 2.136 %	500,000	2.136 %	4 M $
Velan Capital Investment Management LP 2.136 %	500,000	2.136 %	4 M $

Outlook Therapeutics, Inc.

111 South Wood Avenue Unit 100

08830, Iselin

+609 619 3990

http://www.outlooktherapeutics.com

Healthcare

Pharmaceuticals & Medical Research

Biotechnology & Medical Research

Biotechnology & Medical Research

Other Biotechnology & Medical Research

	1st Jan change	Capi.
MODERNA, INC.	+34.14%	51.12B
IQVIA HOLDINGS INC.	-6.54%	39.4B
LONZA GROUP AG	+34.92%	38.48B
ICON PUBLIC LIMITED COMPANY	+12.62%	26.36B
CELLTRION, INC.	-12.11%	26.22B
ALNYLAM PHARMACEUTICALS, INC.	-13.43%	20.96B
UNITED THERAPEUTICS CORPORATION	+43.73%	14.02B
MEDPACE HOLDINGS, INC.	+31.81%	12.49B
BIO-TECHNE CORPORATION	-4.54%	11.61B

Other Biotechnology & Medical Research